This study is a phase II, placebo-controlled clinical trial to evaluate the safety and efficacy of orally administered SP-303, an inhibitor of ileal chloride transport, in patients with HIV-associated disease. Male and female patients with AIDS between 18-60 will be studied. Subjects will qualify for the study of they have a confirmed stool volume >200 gm and >3 liquid bowel movements during the 24-hour screening visit. Qualified subjects will next be randomized and orally adminstered either SP-303 or placebo for the next 96 hours (4 days), ruding which they will remain hospitalized in the GCRC.
Showing the most recent 10 out of 553 publications